BUSINESSMay 26 · 11:50 UTCCNBC TOP

Eli Lilly stock edges higher as company plans nearly $4 billion in vaccine deals

Eli Lilly's stock increased as the company plans nearly $4 billion in vaccine deals to expand into infectious disease research and development.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

Eli Lillyorganizationvaccine dealstopicinfectious disease research and developmenttopic

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

BUSINESSMay 26 · 11:29 UTC
STAT+: Eli Lilly to buy three small vaccine developers
BUSINESSMay 4 · 10:45 UTC
Immune System Biotech Odyssey Seeks $238.3 Million in US IPO
BUSINESSMay 7 · 21:15 UTC
Rocket Lab’s stock rises upon new signs its business is expanding rapidly
TECHNOLOGYMay 6 · 20:45 UTC
Fortinet’s stock rockets higher as earnings help dispel fears of AI disruption
HEALTHMay 11 · 11:53 UTC
Hantavirus cases spark surge in pharma and biotech stocks — here’s why
BUSINESSApr 30 · 16:36 UTC
Novo-Backed Drugmaker Avalyn Soars 44% After $300 Million US IPO